Executive Summary
ESC Congress 2026 delivered two practice-shifting NEJM trials in a single afternoon: TRI-I-HF proved transcatheter tricuspid repair cuts death and heart failure hospitalization through 3 years (HR 0.40, 95% CI 0.29-0.55) versus medical therapy alone, and TAVI-PCI showed valve-first is noninferior to PCI-first in patients with severe AS and CAD (22.2% vs 24.2% composite at 1 year). The tricuspid result is the first hard-outcome win for a transcatheter TR device and vindicates the ESC 2025 Class IIa upgrade; TAVI-PCI hands operators sequencing flexibility that most heart teams were already improvising. Together they tighten the transcatheter case in TR and simplify the workflow in AS — while leaving the durability question open in both.
- TRI-I-HF: 3-year freedom from death or HF hospitalization was 52.4% with tricuspid repair vs 21.0% with medical therapy (P<0.001), 30-day major adverse events 5.9% — NEJM.
- TAVI-PCI: In 986 randomized patients, TAVR-first met noninferiority for a 6-item composite with risk difference -2.0 percentage points — NEJM.
- STS/ACC TVT Registry: high-volume TAVR centers (>300/yr) had lower MACCE despite higher-risk patients (aHR 0.40 vs low-volume); empirical threshold identified at 314 cases/year — JAHA.
- Baseline aortic valve mean gradient inversely predicted 1-year mortality after Evolut TAVR in 80,429 registry patients — 20.9% mortality at MG <20 mmHg vs 9.3% at ≥40 mmHg — JAHA.
- Tendyne transapical TMVR mid-term single-center data (N=30): 100% device success, but 50% all-cause mortality at 2.8 years and 30% HF rehospitalization — ICVTS.
What to watch: Medtronic reports fiscal Q1 earnings September 1 — first read on structural heart momentum against the ESC late-breaker cycle.
Aortic Valve (TAVR/TAVI)
[NOTABLE] The TAVI-PCI trial in NEJM randomized 986 patients across 48 European centers to TAVR-first or PCI-first; the primary composite (death, MI, revascularization, valve/procedure/HF rehospitalization, major bleeding) occurred in 22.2% vs 24.2% at 1 year, meeting the 6.6-point noninferiority margin. A notable operational finding: many TAVR-first patients never required PCI, because clinical reassessment after valve treatment changed the ischemic calculus. Neither ACC/AHA 2020 nor ESC 2025 dictates sequencing — both defer to heart-team judgment — and this trial validates that flexibility with randomized evidence.
A separate JAHA analysis of 80,429 Evolut TAVR patients from STS/ACC TVT showed 1-year mortality of 20.9% in the lowest mean gradient stratum (10-<20 mmHg) versus 9.3% at ≥40 mmHg — with mortality rising monotonically as gradient fell (adjusted HR 0.93 per unit, P<0.001). Low-gradient patients still saw substantial KCCQ gains, so quality-of-life benefit persists even where survival does not. This registry finding, non-randomized and subject to selection bias, reinforces why low-flow low-gradient AS remains one of the field's hardest diagnostic and prognostic problems. The volume-outcomes analysis in the same issue identified 314 cases/year as the empirical MACCE inflection point; ACC/AHA operator and center volume requirements remain looser than this signal warrants.
A separate NEJM-family analysis reported by MedPage Today tentatively backs DOACs over antiplatelets for post-TAVR thromboprophylaxis — a reversal of POPular-TAVI-era practice; the ACC/AHA 2020 default remains single antiplatelet therapy in patients without an anticoagulation indication. And 10-year Japanese single-center data found no overall association between PPM and mortality after TAVR, though severe PPM predicted CV mortality in low-risk patients (HR 3.11) — a finding that argues against complacency in the <70 cohort ESC 2025 assigns to SAVR precisely because long-term hemodynamic consequences compound over time.
Mitral Valve (MitraClip, PASCAL, TMVR)
Transapical TMVR mid-term data continues to underwhelm. A single-center Italian series of 30 Tendyne patients (mean age 74.6, EuroSCORE II 7.7%) reported 100% technical success and no more than mild residual MR at 2.8 years, with 94% in NYHA II — but 50% all-cause mortality, 27% CV mortality, and 30% HF rehospitalization over the same interval. Small sample, non-randomized, single-center — flag these numbers accordingly. This is a comorbidity-heavy population that would not have qualified for TEER in COAPT, and hemodynamic success did not translate into event-free survival. Neither ACC/AHA 2020 nor ESC 2025 grants transapical TMVR more than a Class IIb toehold; these numbers explain why. By contrast, ESC 2025 upgraded TEER for ventricular secondary MR to Class I based on COAPT and RESHAPE-HF2, and surgical MV repair remains the Class I standard for primary MR when a durable repair is expected. Transapical TMVR sits below both on every current evidence hierarchy.
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] TRI-I-HF in NEJM is the first randomized trial to show that transcatheter tricuspid repair reduces hard outcomes — not just quality of life. In 360 patients (2:1 randomization) with symptomatic severe TR and elevated HF-event risk, the win ratio for the hierarchical 1-year composite (death, HF hospitalization, QoL) was 2.42 (95% CI 1.76-3.33, P<0.001), and 3-year freedom from death or HF hospitalization was 52.4% vs 21.0% (HR 0.40, P<0.001). Thirty-day major adverse events were 5.9%. This moves the transcatheter TR story beyond TRILUMINATE Pivotal's QoL-driven win.
The surgical comparator is thin by design. Isolated tricuspid surgery historically carried 8-20% operative mortality, though contemporary series with earlier referral show improved outcomes. ESC 2025 rates transcatheter TV treatment Class IIa for high-risk symptomatic severe TR without severe RV dysfunction or pre-capillary PH; ACC/AHA 2020 did not address transcatheter TR at all. TRI-I-HF is the strongest evidence yet supporting ESC's forward position and will pressure the next ACC/AHA update. Enrollment excluded severe RV dysfunction and advanced pre-capillary PH — the too-late-referral population where surgical registries have also struggled — so this is not a green light for salvage cases. Coverage in MedPage Today and Cardiovascular Business frames this as inflection-point evidence.
Surgical vs. Transcatheter Comparisons
No new head-to-head SAVR-vs-TAVR RCTs today. The day's evidence pushes the transcatheter case forward in TR and lateral in AS: TAVI-PCI removes a workflow disincentive to TAVR without addressing the durability comparator that keeps ACC/AHA 2020's SAVR-preferred zone intact for patients <65 and ESC 2025's for those <70. The registry mortality signal in low-gradient AS should prompt surgeons and interventionalists alike to interrogate why these patients die at more than double the rate of high-gradient peers — physiologic AS severity, occult HFpEF, and end-stage myocardial disease all sit on that differential.
Preprint Highlights
A MAUDE analysis of 376 bailout cardiac surgery events after TAVR from 2016-2026 found 40.9% reported mortality, with valve embolization/migration/malposition the most frequent trigger (32.4%) and ventricular perforation/laceration the deadliest (74.1% mortality; OR 4.86). Valve explantation with SAVR was associated with lower mortality (18.9%; OR 0.29). MAUDE is voluntary and reporting-biased — these are safety signals, not incidence estimates — but the mortality gradient across operative pathways underscores why the ESC 2025 lifetime-management framework emphasizes anatomical planning at the index procedure. A separate 40-patient prospective Bern study identified a butyrate-IL-18 axis after TAVI: circulating butyrate declined post-procedure and inversely correlated with IL-18 elevation (rho 0.668, P<0.001). Mechanistic, hypothesis-generating.
Device & Technology
A new German multicenter RCT (NCT07794306) was posted comparing Meril Octapro+ against Abbott Navitor/Navitor Vision in small aortic annuli — a 510-patient head-to-head that will bear directly on the LANDMARK-era balloon-vs-self-expanding debate in the annulus-size subgroup where prosthesis-patient mismatch remains most consequential.
Industry & Market
Edwards Lifesciences drew heavy analyst and options-flow attention as ESC opened. A simplywall.st valuation note argued EW is undervalued on TAVR platform maturation plus EVOQUE tricuspid ramp — a thesis the TRI-I-HF results (competitor Abbott's TriClip system) complicate by strengthening the entire transcatheter TR category, EVOQUE included. MassDevice reported EW's strategy VP will depart in 2027 — leadership continuity is a soft signal to monitor. IBD flagged unusually narrow market breadth with EW, Fortinet and UBS in focus.
Financial Analysis
TRI-I-HF expands the addressable transcatheter TR market and adds urgency to Abbott's TriClip/EVOQUE competitive frame — but the trial's exclusion of severe RV dysfunction and advanced PH means real-world case volume growth depends on referral pattern change more than device availability. TAVI-PCI likely accelerates TAVR volumes at the margin by removing sequencing friction, but does nothing for the durability question that anchors low-risk penetration. The volume-outcomes JAHA paper carries its own commercial weight: if payers and regulators internalize a 314 case/year threshold, program consolidation pressure builds — favoring high-volume incumbents.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $90.75 (+0.89%); 6-month +4.09%; 52-week $72.30-$96.29
- Market cap $52.3B; trailing P/E 53.7; forward P/E 26.9; beta 0.85
- Analyst target $100.96 (26 analysts, buy consensus)
- Next earnings 2026-10-29 (EPS est $0.74; revenue est $1.68B)
EW held ground into ESC despite EVOQUE facing a strengthened Abbott TriClip narrative from TRI-I-HF. Options flow and insider ESPP transactions reported this week are noise; the earnings print in October is the next real catalyst.
Medtronic (MDT)
- Close: $90.65 (+0.76%); 6-month -6.00%; 52-week $73.31-$106.33
- Market cap $116.0B; trailing P/E 24.4; forward P/E 14.2; beta 0.57
- Analyst target $98.84 (25 analysts, buy)
- Next earnings 2026-09-01 (EPS est $1.39; revenue est $9.54B) — tomorrow
Evolut TAVR remains the structural heart franchise anchor; watch for commentary on TAV-in-TAV positioning and any read on the low-gradient AS mortality signal that JAHA highlighted.
Abbott (ABT)
- Close: $110.36 (-1.10%); 6-month -1.99%; 52-week $81.97-$137.49
- Market cap $191.0B; trailing P/E 36.4; forward P/E 18.2; beta 0.58
- Analyst target $120.20 (25 analysts, buy)
- Next earnings 2026-10-14 (EPS est $1.42; revenue est $12.99B)
Abbott is the clearest beneficiary of TRI-I-HF: TriClip owns the transcatheter TR TEER category clinically validated today. Structural heart is a modest share of ABT's revenue but a strategic growth wedge.
Boston Scientific (BSX)
- Close: $48.30 (+3.49%); 6-month -36.63%; 52-week $42.20-$109.50
- Market cap $70.0B; trailing P/E 19.6; forward P/E 14.1; beta 0.57
- Analyst target $62.69 (29 analysts, buy)
- Next earnings 2026-10-28 (EPS est $0.81; revenue est $5.26B)
BSX bounced 3.5% but remains down over a third across six months. Structural heart exposure via Acurate and Sentinel remains under competitive pressure.
Anteris Technologies (AVR.AX)
- Close: A$11.91 (-0.50%); 6-month +35.34%; 52-week A$5.20-A$15.47
- Market cap A$1.2B; forward P/E -5.5 (pre-revenue on lead device)
DurAVR next-gen TAVR platform remains a speculative play on the durability differentiation thesis — the exact gap the ACC/AHA 2020 and ESC 2025 guidelines flag for younger patients.
Market outlook: the transcatheter valve trade is bifurcating. TR is now a validated category with hard-outcome evidence; TAVR is a mature workflow business where volume-outcomes data may drive consolidation. Investors should separate the two.
Clinical Trial Updates
Aortic
- NCT07794306 — Balloon- Versus Self-Expanding Intraannular TAVI in Small Aortic Annuli. Status: Not Yet Recruiting. Enrollment: 510. Sponsor: Universitätsklinikum Hamburg-Eppendorf. Interventions: Meril Octapro+ vs Abbott Navitor/Navitor Vision. A direct head-to-head in the annulus-size cohort where PPM risk is highest — this trial extends the LANDMARK framework to a subgroup that matters clinically.
Social & Conference Highlights
ESC Congress 2026 in Munich delivered the two NEJM late-breakers driving today's edition (TAVI-PCI, TRI-I-HF), a JACC late-breaker on TAVR in paradoxical low-flow low-gradient AS (REBOOT-PARADOX), and the DOAC-after-TAVR readout. TCTMD's Structural Heart Journal+ is compiling the meeting archive.
Next up: Medtronic's fiscal Q1 print September 1 — the first Wall Street reaction to a week that reset the transcatheter TR frame and gave TAVR operators procedural flexibility they didn't have Friday.